Last reviewed · How we verify
Comparator: cefotetan
Cefotetan is a second-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins.
Cefotetan, developed by Merck Sharp & Dohme LLC, is a second-generation cephalosporin antibiotic used primarily for the prevention and treatment of surgical site infections. It has completed a Phase 3 trial comparing its efficacy to another marketed drug in colorectal surgery patients. The drug lacks an FDA label but has potential in the surgical infection market.
At a glance
| Generic name | Comparator: cefotetan |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | Second-generation cephalosporin |
| Target | Penicillin-binding proteins (PBPs) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Cefotetan works by disrupting the cross-linking of peptidoglycan in the bacterial cell wall, leading to cell wall instability and bacterial death. It has broad-spectrum activity against gram-positive and gram-negative bacteria, including anaerobes, making it useful for surgical prophylaxis and mixed aerobic-anaerobic infections. The drug is bactericidal and typically administered intravenously or intramuscularly.
Approved indications
- Surgical prophylaxis
- Mixed aerobic-anaerobic infections
- Gynecological infections
- Intra-abdominal infections
Common side effects
- Diarrhea
- Nausea
- Hypersensitivity reactions
- Phlebitis at injection site
- Elevated liver enzymes
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Comparator: cefotetan CI brief — competitive landscape report
- Comparator: cefotetan updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI